Provided by Tiger Trade Technology Pte. Ltd.

Monopar Therapeutics

77.97
0.0000
Post-market: 77.970.00000.00%19:30 EDT
Volume:107.62K
Turnover:8.38M
Market Cap:521.04M
PE:-35.76
High:80.00
Open:78.36
Low:77.03
Close:77.97
52wk High:124.82
52wk Low:50.07
Shares:6.68M
Float Shares:4.48M
Volume Ratio:0.60
T/O Rate:2.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1804
EPS(LYR):-1.8509
ROE:-19.50%
ROA:-14.64%
PB:3.98
PE(LYR):-42.13

Loading ...

Lake Street Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Jun 01

Monopar presents Phase 2 data showing ALXN1840 stabilizes liver disease in Wilson patients at EASL 2026

Reuters
·
Jun 01

Monopar says Phase 2 trial shows ALXN1840 improves copper balance in Wilson disease

Reuters
·
May 20

Analysts’ Top Healthcare Picks: Monopar Therapeutics Inc (MNPR), Voyager Therapeutics (VYGR)

TIPRANKS
·
May 18

Morgan Stanley Keeps Their Buy Rating on Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
May 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 15

Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
May 15

Monopar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

Monopar Therapeutics Q1 EPS $(0.46) Beats $(0.83) Estimate

Benzinga Earnings
·
May 15

Monopar net loss widens to $3.89 million in Q1 FY26

Reuters
·
May 15

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
May 15

Monopar Therapeutics Inc - on Track to Submit Nda to FDA in Mid-2026

THOMSON REUTERS
·
May 15

Monopar Therapeutics Inc expected to post a loss of 84 cents a share - Earnings Preview

Reuters
·
May 08

Monopar Therapeutics announces annual shareholder meeting

Reuters
·
May 01

Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON)

TIPRANKS
·
Apr 21

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)

TIPRANKS
·
Apr 21

Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840

TIPRANKS
·
Apr 20

Monopar says Phase 3 trial shows ALXN1840 beats standard care in neurologic Wilson disease

Reuters
·
Apr 20

Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading

TIPRANKS
·
Apr 07

Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street

TIPRANKS
·
Mar 30